[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369625-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369625-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","combination-of-kras-aso-and-rig-i-agonist-in-extracellular-vesicles-transforms-the-tumor-microenvironment-towards-effective-treatment-of-kras-dependent-cancers","Combination of KRAS ASO and RIG-I agonist in extracellular vesicles transforms the tumor microenvironment towards effective treatment of KRAS-dependent cancers","","Mutations in the KRAS gene drive many cancers, yet targeting KRAS mutants remains challenging. This research uses a nucleic acid-based therapy delivered via extracellular vesicles (EVs) to simultaneously inhibit KRAS mutants and activate the RIG-I pathway, aiming to enhance anti-tumor immunity. Antisense oligonucleotides against KRAS mutants and RIG-I immunomodulatory RNA were loaded into EVs and tested in colorectal and NSCLC models, plus patient-derived pancreatic cancer organoids. Outcomes included tumor microenvironment remodeling, dendritic cell activation, T cell memory formation, interferon upregulation, immunogenic tumor cell death, and improved survival without adverse effects.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/combination-of-kras-aso-and-rig-i-agonist-in-extracellular-vesicles-transforms-the-tumor-microenvironment-towards-effective-treatment-of-kras-dependent-cancers/369625/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/combination-of-kras-aso-and-rig-i-agonist-in-extracellular-vesicles-transforms-the-tumor-microenvironment-towards-effective-treatment-of-kras-dependent-cancers/369625.png","ImageObject",300,407,{"name":42,"@type":43},"Aditya","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What therapeutic strategy does the paper propose for KRAS-dependent cancers?","Question",{"text":63,"@type":64},"It delivers antisense oligonucleotides against KRAS mutants and a RIG-I agonist immunomodulatory RNA via extracellular vesicles to both inhibit KRAS mutants and activate the RIG-I pathway.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were the treatment effects evaluated?",{"text":68,"@type":64},"The study tested colorectal and non-small cell lung cancer tumor models, as well as patient-derived pancreatic cancer organoids, assessing tumor microenvironment changes, dendritic cell activation, and T cell memory formation, alongside tumor development and overall survival.",{"name":70,"@type":61,"acceptedAnswer":71},"What key outcomes were reported in KRAS-dependent models?",{"text":72,"@type":64},"The KRAS-ASO plus immRNA combination induced immunogenic tumor cell death, upregulated interferons, shifted the tumor microenvironment toward immunogenicity, activated dendritic cells, promoted memory T cell formation, and extended survival without adverse effects in the aggressive NSCLC model.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369625,1790209854,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},962085564549,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Theranostics 2025, Vol. 15, Issue 14 6818  \nIvyspring  \nInternational Publisher  \nTheranostics  \n2025; 15(14): 6818-6838. doi: 10.7150/thno.105519  \nResearch Paper  \nCombination of KRAS ASO and RIG-I agonist in extracellular vesicles transforms the tumor microenvironment towards effective treatment of KRAS-dependent cancers  \nCao Dai Phung1\\#, Trinh T.T. Tran1,13\\#, Brendon Zhi Jie Yeo1, Rebecca Carissa Prajogo1, Evelyn Saudjana1, Eric Yew Meng Yeo1, Chang Gao1, Phuong H.D. Nguyen1, Migara Kavishka Jayasinghe1, Xuan T.T. Dang1, Celest Phang Lixuan4,5, Trinh Mai Nguyen4,5, Boya Peng1, Anh Hong Le1, Tram T.T Nguyen1, Gloria Mei En Chan6, Yuin-Han Loh7,8,9,11, Boon Cher Goh1,2, Wai Leong Tam2,3, Glenn Kunnath Bonney16, Dahai Luo4,5, Minh T.N. Le1,11,12,14,15􀀍  \n1. Department of Pharmacology and Institute for Digital Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.  \n2. Cancer Science Institute of Singapore, National University of Singapore, Singapore.  \n3. Genome Institute of Singapore, A*STAR, Singapore.  \n4. Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.  \n5. Institute of Structural Biology, Nanyang Technological University, Singapore.  \n6. Synthetic Biology Translational Research Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.  \n7. Cell Fate Engineering and Therapeutics Laboratory, A*STAR Institute of Molecular and Cell Biology, Singapore, 138673, Singapore.  \n8. Department of Biological Sciences, National University of Singapore, Singapore, 117543, Singapore.  \n9. Integrative Sciences and Engineering Programme (ISEP), NUS Graduate School, National University of Singapore, 21 Lower Kent Ridge Road, Singapore, 119077, Singapore.  \n10. Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117593, Singapore.  \n11. Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore.  \n12. Institute of Molecular and Cell Biology, A*STAR, Singapore.  \n13. Vingroup Science and Technology Scholarship Program, Vin University, Hanoi, Vietnam.  \n14. Nanomedicine Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.  \n15. Cancer Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.  \n16. Institute of Health Innovation & Technology, National University of Singapore, Singapore.  \n\\#C.D. Phung and T.T.T. Tran contributed equally to this work.  \n􀀍 Corresponding author: Dr. Le Thi Nguyet Minh; [phcltnm@nus.edu.sg](phcltnm@nus.edu.sg).  \n© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)). See [https://ivyspring.com/terms](https://ivyspring.com/terms) for full terms and conditions.  \nReceived: 2024.10.20; Accepted: 2025.02.23; Published: 2025.06.09  \nAbstract  \n\n| Rationale: Mutations in the KRAS gene drive many cancers, yet targeting KRAS mutants remains a challenge. Here, we address this hurdle by utilizing a nucleic acid-based therapeutic strategy delivered via extracellular vesicles (EVs) to simultaneously inhibit KRAS mutants and activate the RIG-I pathway, aiming to enhance anti-tumor immunity.\u003Cbr>Methods: Antisense oligonucleotides against KRAS mutants (KRAS ASOs) and RIG-I agonist immunomodulatory RNA (immRNA) were loaded into EVs and administered to KRAS-mutant cancer models. The therapeutic effects were assessed in colorectal and non-small cell lung cancer (NSCLC) tumor models, as well as patient-derived pancreatic cancer organoids. Immune responses were evaluated by analyzing tumor microenvironment’s changes, dendritic cell activation, and T cell memory formation. The treatment efficacy was evaluated based on the tumor development and overall survival.\u003Cbr>Results: The KRAS-ASO and ","cbCaioAlMlrC77mY","https://ap.wps.com/l/cbCaioAlMlrC77mY","pdf",10255332,21,"English","# Abstract\n## Rationale\n## Methods\n## Results\n## Conclusions\n# Keywords\n# Introduction","[{\"question\":\"What therapeutic strategy does the paper propose for KRAS-dependent cancers?\",\"answer\":\"It delivers antisense oligonucleotides against KRAS mutants and a RIG-I agonist immunomodulatory RNA via extracellular vesicles to both inhibit KRAS mutants and activate the RIG-I pathway.\"},{\"question\":\"How were the treatment effects evaluated?\",\"answer\":\"The study tested colorectal and non-small cell lung cancer tumor models, as well as patient-derived pancreatic cancer organoids, assessing tumor microenvironment changes, dendritic cell activation, and T cell memory formation, alongside tumor development and overall survival.\"},{\"question\":\"What key outcomes were reported in KRAS-dependent models?\",\"answer\":\"The KRAS-ASO plus immRNA combination induced immunogenic tumor cell death, upregulated interferons, shifted the tumor microenvironment toward immunogenicity, activated dendritic cells, promoted memory T cell formation, and extended survival without adverse effects in the aggressive NSCLC model.\"}]","Combination of KRAS ASO and RIG-I agonist in extracellular vesicles transforms the tumor microenvironment towards effective treatment of KRAS-dependent cancers | PDF",1790183726,53,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/791e711ddf6660fe02c9201035d39f9e.webp",983,1272,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/41ef4a7fb81d3225d49a607493344d51.webp",982,1270,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/56641d5077a9c57fead334c91f64f22e.webp",981,1269,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/da83c2871dc34e09dcdc957229d829c3.webp",980,1268]